Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]
Elevation Oncology, Inc. - Common stock (ELEV)
Company Research
Source: Yahoo! Finance
-- Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting; on-track to nominate development candidate in 2H 2024 -- -- Raised $44.2 million year-to-date through ATM facility, extending cash runway into 2026 -- BOSTON May 2, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024 , and highlighted recent business achievements. "In recent months, we focused on advancing our growing pipeline of differentiated ADCs, each with broad therapeutic potential, and extending our cash runway into 2026, beyond upcoming milestones for EO-3021 and our HER3-ADC program," said Joseph Ferra , President and Chief Executive Officer of Elevation Oncology. "At AACR, we shared preclinical proof-of-concept d
Show less
Read more
Impact Snapshot
Event Time:
ELEV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELEV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELEV alerts
High impacting Elevation Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ELEV
News
- Elevation Oncology, Inc. (NASDAQ: ELEV) is now covered by analysts at Stephens. They set an "overweight" rating and a $8.00 price target on the stock.MarketBeat
- Elevation Oncology, Inc. (NASDAQ: ELEV) is now covered by analysts at Stephens. They set an "overweight" rating and a $8.00 price target on the stock.MarketBeat
- Elevation Oncology to Present at the Citizens JMP Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
- Elevation Oncology to Present at the Citizens JMP Life Sciences ConferencePR Newswire
- Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling [Seeking Alpha]Seeking Alpha
ELEV
Sec Filings
- 5/10/24 - Form EFFECT
- 5/9/24 - Form 424B3
- 5/2/24 - Form S-3
- ELEV's page on the SEC website